Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 781780, 5 pages
http://dx.doi.org/10.1155/2014/781780
Clinical Study

Xuezhikang Therapy Increases miR-33 Expression in Patients with Low HDL-C Levels

1Department of Geriatric Cardiology, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China
2National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Received 12 June 2013; Revised 1 November 2013; Accepted 18 November 2013; Published 23 January 2014

Academic Editor: Holly Soares

Copyright © 2014 Ruihua Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. MicroRNA-33a and -b (miR-33a/b) have been revealed to be posttranscriptional regulators of HDL metabolism. Xuezhikang (XZK) is a marked natural HDL-raising polypill. We aim to evaluate the effects of XZK on the expression of circulating miR-33a/b in patients with low plasma HDL-C levels. Methods. A total of 42 participating patients with low baseline levels of HDL cholesterol were assigned to receive an XZK capsule, 600 mg twice daily for 6 months. The expression of circulating miR-33a/b was detected at baseline and after XZK therapy measured with quantitative reverse-transcription (RT) polymerase chain reaction (PCR). Results. The mean (SD) HDL-C level after XZK treatment was 1.19 (0.13) mmol/L, representing an increase of 11.2% from baseline (). Q-PCR analysis of plasma miRNAs revealed an increase in relative miR-33a/b expression with XZK treatment. The miR-33a expression was raised from 0.81 to 1.73 (); miR-33b expression was increased from 1.2 to 2.75 (). The changes of miR-33a and miR-33b were inversely related to the posttreatment LDL-C levels (, ; , , resp.). Conclusion. In patients with low HDL-C levels, XZK therapy raised plasma levels of miR-33a and miR-33b, which may inhibit cellular cholesterol export and limit the HDL-raising effect of XZK.